10x Genomics, a leader in spatial biology and single-cell analysis, has joined forces with the Genome Institute of Singapore (A*STAR GIS) to launch an ambitious new research project called TISHUMAP. This collaboration aims to transform how we understand and treat diseases like cancer and inflammation by combining cutting-edge AI, spatial genomics, and advanced tissue imaging.
What is TISHUMAP?
TISHUMAP stands for “Inference from Integrated Spatialomics and Histology with Multimodal AI and Phenotypes.” In simple terms, it’s a research initiative focused on studying how cells behave in their natural environment using powerful AI tools and a state-of-the-art technology called the Xenium platform developed by 10x Genomics.
What They’re Doing
The team will analyze around 2,500 preserved tissue samples from patients with colorectal, gastric, and liver cancers.
Unlike traditional methods that require breaking down tissues, the Xenium platform allows researchers to study intact tissues at the single-cell level, helping them see how individual cells interact and function in real-time.
By combining this data with AI analysis, scientists hope to uncover hidden patterns that could lead to new drug targets, biomarkers, and personalized treatment options.
Why This Matters
This collaboration will not only enhance our understanding of complex diseases but also speed up the discovery of new therapies and diagnostic tools. With smart lab workflows, AI-powered data management, and customized gene panels, the project represents a huge step toward precision medicine—treatments tailored to individual patients based on their biology.
What the Experts Are Saying
🗣️ Dr. Shyam Prabhakar, Associate Director at A*STAR GIS, shared:
“Partnering with 10x Genomics on TISHUMAP is a game-changer. Together, we’re building a strong foundation for smarter diagnostics and effective treatments, especially for early and advanced cancer stages.”
🗣️ Serge Saxonov, CEO of 10x Genomics, said:
“Our Xenium platform is unlocking the hidden patterns of biology. Working with A*STAR GIS lets us push boundaries and develop the tools scientists need to create better therapies and improve health outcomes worldwide.”
Bottom Line:
This partnership is a major leap forward in biomedical research. By merging spatial biology with AI, 10x Genomics and A*STAR GIS are making it possible to see diseases in an entirely new way—and ultimately helping bring faster, more personalized treatments to patients.
Request a customized case study tailored to your business needs and gain deeper insights into healthcare market strategies: sales@towardshealthcare.com
Asia-Pacific is poised to become the fastest-growing region in the small-scale bioreactors market over the coming years, driven by several… Read More
North America continues to dominate the global neurostimulation devices market, holding a significant 60% share in 2024. Several key factors… Read More
AAVnerGene Inc., an innovative biotech company based in Rockville, MD, known for its cutting-edge AAV tissue-targeted delivery and manufacturing technologies,… Read More
Jiangsu Hengrui Pharmaceuticals Co., Ltd. and IDEAYA Biosciences, Inc. are set to showcase their groundbreaking research at the IASLC 2025… Read More
QIAGEN has launched its new QIAseq xHYB long-read panels, a cutting-edge solution designed to explore the complexities of genomically diverse… Read More
Kyoto, Japan July 2025 A groundbreaking collaboration has been formed between Kansai Startup Academia Coalition (KSAC), led by Kyoto University,… Read More